243 related articles for article (PubMed ID: 30538204)
1. Crystal structure of the human NK
Yin J; Chapman K; Clark LD; Shao Z; Borek D; Xu Q; Wang J; Rosenbaum DM
Proc Natl Acad Sci U S A; 2018 Dec; 115(52):13264-13269. PubMed ID: 30538204
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.
Cascieri MA; Ber E; Fong TM; Hale JJ; Tang F; Shiao LL; Mills SG; MacCoss M; Sadowski S; Tota MR; Strader CD
Eur J Pharmacol; 1997 May; 325(2-3):253-61. PubMed ID: 9163573
[TBL] [Abstract][Full Text] [Related]
3. Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography.
Chen S; Lu M; Liu D; Yang L; Yi C; Ma L; Zhang H; Liu Q; Frimurer TM; Wang MW; Schwartz TW; Stevens RC; Wu B; Wüthrich K; Zhao Q
Nat Commun; 2019 Feb; 10(1):638. PubMed ID: 30733446
[TBL] [Abstract][Full Text] [Related]
4. Mapping substance P binding sites on the neurokinin-1 receptor using genetic incorporation of a photoreactive amino acid.
Valentin-Hansen L; Park M; Huber T; Grunbeck A; Naganathan S; Schwartz TW; Sakmar TP
J Biol Chem; 2014 Jun; 289(26):18045-54. PubMed ID: 24831006
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists.
Schöppe J; Ehrenmann J; Klenk C; Rucktooa P; Schütz M; Doré AS; Plückthun A
Nat Commun; 2019 Jan; 10(1):17. PubMed ID: 30604743
[TBL] [Abstract][Full Text] [Related]
6. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the effect of homocysteinylation of substance P on its binding to the NK1 receptor using molecular dynamics simulation.
Davoudmanesh S; Mosaabadi JM
J Mol Model; 2018 Jun; 24(7):177. PubMed ID: 29943287
[TBL] [Abstract][Full Text] [Related]
8. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.
Hargreaves R
J Clin Psychiatry; 2002; 63 Suppl 11():18-24. PubMed ID: 12562139
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
[TBL] [Abstract][Full Text] [Related]
10. The role of the N-terminal and mid-region residues of substance P in regulating functional selectivity at the tachykinin NK1 receptor.
Perrine SA; Beard DJ; Young JK; Simmons MA
Eur J Pharmacol; 2008 Sep; 592(1-3):1-6. PubMed ID: 18634782
[TBL] [Abstract][Full Text] [Related]
11. GPCR large-amplitude dynamics by
Pan B; Liu D; Yang L; Wüthrich K
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2122682119. PubMed ID: 35377814
[TBL] [Abstract][Full Text] [Related]
12. Gly166 in the NK1 receptor regulates tachykinin selectivity and receptor conformation.
Ciucci A; Palma C; Riitano D; Manzini S; Werge TM
FEBS Lett; 1997 Oct; 416(3):335-8. PubMed ID: 9373180
[TBL] [Abstract][Full Text] [Related]
13. Substance P and the Neurokinin-1 Receptor: The New CRF.
Schank JR; Heilig M
Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
[TBL] [Abstract][Full Text] [Related]
14. Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists.
Gether U; Johansen TE; Schwartz TW
J Biol Chem; 1993 Apr; 268(11):7893-8. PubMed ID: 7681831
[TBL] [Abstract][Full Text] [Related]
15. Neurokinin-1 receptor antagonists: a comprehensive patent survey.
Huang SC; Korlipara VL
Expert Opin Ther Pat; 2010 Aug; 20(8):1019-45. PubMed ID: 20533894
[TBL] [Abstract][Full Text] [Related]
16. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
17. Identifying a putative common binding site shared by substance P receptor and an anti-substance P monoclonal antibody.
Amati V; Werge TM; Cattaneo A; Tramontano A
Protein Eng; 1995 Apr; 8(4):403-8. PubMed ID: 7567926
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
19. Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors.
Palma C; Nardelli F; Manzini S; Maggi CA
Br J Cancer; 1999 Jan; 79(2):236-43. PubMed ID: 9888463
[TBL] [Abstract][Full Text] [Related]
20. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
